Skip to Main Content

Author Details

Clayton A Smith
University of Colorado, Aurora CO.
1987
93
36
PMIDPaper TitleJournal TitlePublished Year
37358260A Novel Type of Monocytic Leukemia Stem Cell Revealed by the Clinical Use of Venetoclax-Based Therapy.Cancer Discov2023
37185614Venetoclax is safe and tolerable as post-transplant maintenance therapy for AML patients at high risk for relapse.Bone Marrow Transplant2023
37051756Higher-dose venetoclax with measurable residual disease-guided azacitidine discontinuation in newly diagnosed acute myeloid leukemia.Haematologica2023
34645926Venetoclax and azacitidine followed by allogeneic transplant results in excellent outcomes and may improve outcomes versus maintenance therapy among newly diagnosed AML patients older than 60.Bone Marrow Transplant2022
33109736Exploiting Protein Translation Dependence in Multiple Myeloma with Omacetaxine-Based Therapy.Clin Cancer Res2021
34610123Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia.Blood Adv2021
34661159Hyperthermia Selectively Destabilizes Oncogenic Fusion Proteins.Blood Cancer Discov2021
33375853The propriety of upgrading responses to venetoclaxâ¿¿+â¿¿azacitidine in newly diagnosed patients with acute myeloid leukemia.Leuk Lymphoma2021
32442301Adult cord blood transplant results in comparable overall survival and improved GRFS vs matched related transplant.Blood Adv2020
33884374Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells.Nat Cancer2020
31756539Unlicensed Umbilical Cord Blood Units Provide a Safe and Effective Graft Source for a Diverse Population: A Study of 2456 Umbilical Cord Blood Recipients.Biol Blood Marrow Transplant2020
31974170Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia.Cancer Discov2020
32634235Glasdegib as maintenance therapy for patients with AML and MDS patients at high risk for postallogeneic stem cell transplant relapse.Blood Adv2020
32822582Nicotinamide Metabolism Mediates Resistance to Venetoclax in Relapsed Acute Myeloid Leukemia Stem Cells.Cell Stem Cell2020
32311014Measurement of ex vivo resistance to proteasome inhibitors, IMiDs, and daratumumab during multiple myeloma progression.Blood Adv2020
30753831Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells.Cancer Cell2019
31648312Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia.Blood Adv2019
31009835Sequential azacitidine and lenalidomide for patients with relapsed and refractory acute myeloid leukemia: Clinical results and predictive modeling using computational analysis.Leuk Res2019
30852438Low ferroportin expression in AML is correlated with good risk cytogenetics, improved outcomes and increased sensitivity to chemotherapy.Leuk Res2019
31136781CD123 CAR T cells for the treatment of myelodysplastic syndrome.Exp Hematol2019
29684565Thiotepa-Based Intensified Reduced-Intensity Conditioning Adult Double-Unit Cord Blood Hematopoietic Stem Cell Transplantation Results in Decreased Relapse Rate and Improved Survival Compared with Transplantation Following Standard Reduced-Intensity Conditioning: A Retrospective Cohort Comparison.Biol Blood Marrow Transplant2018
29910151AMPK/FIS1-Mediated Mitophagy Is Required for Self-Renewal of Human AML Stem Cells.Cell Stem Cell2018
30423294Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells.Cancer Cell2018
30420752Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia.Nat Med2018
27789277Erratum to "Filgrastim-Stimulated Bone Marrow Compared with Filgrastim-Mobilized Peripheral Blood in Myeloablative Sibling Allografting for Patients with Hematologic Malignancies: A Randomized Canadian Blood and Marrow Transplant Group Study" [Biol Blood Marrow Transplant 2016;22:1410-1415].Biol Blood Marrow Transplant2017
28280079Targeted therapy for a subset of acute myeloid leukemias that lack expression of aldehyde dehydrogenase 1A1.Haematologica2017
28935847CD56<sup>bright</sup> natural killer regulatory cells in filgrastim primed donor blood or marrow products regulate chronic graft-<i>versus</i>-host disease: the Canadian Blood and Marrow Transplant Group randomized 0601 study results.Haematologica2017
28679093PD-1 Blockade in Mediastinal Gray-Zone Lymphoma.N Engl J Med2017
28881356Aldehyde dehydrogenase 1B1: a novel immunohistological marker for colorectal cancer.Br J Cancer2017
28645468ALDHs in normal and malignant hematopoietic cells: Potential new avenues for treatment of AML and other blood cancers.Chem Biol Interact2017
27154847Filgrastim-Stimulated Bone Marrow Compared with Filgrastim-Mobilized Peripheral Blood in Myeloablative Sibling Allografting for Patients with Hematologic Malignancies: A Randomized Canadian Blood and Marrow Transplant Group Study.Biol Blood Marrow Transplant2016
26389776Clonality of neutrophilia associated with plasma cell neoplasms: report of a SETBP1 mutation and analysis of a single institution series.Leuk Lymphoma2016
27888238Rational design of a parthenolide-based drug regimen that selectively eradicates acute myelogenous leukemia stem cells.J Biol Chem2016
27573247Rational Design of a Parthenolide-based Drug Regimen That Selectively Eradicates Acute Myelogenous Leukemia Stem Cells.J Biol Chem2016
25082785Targeting acute myeloid leukemia stem cells: a review and principles for the development of clinical trials.Haematologica2014
22987615Deletion of the RNA-editing enzyme ADAR1 causes regression of established chronic myelogenous leukemia in mice.Int J Cancer2013
24061865Effects of the aldehyde dehydrogenase inhibitor disulfiram on the plasma pharmacokinetics, metabolism, and toxicity of benzaldehyde dimethane sulfonate (NSC281612, DMS612, BEN) in mice.Cancer Chemother Pharmacol2013
22640008Allogeneic haematopoietic stem cell transplantation for chronic lymphocytic leukaemia: outcome in a 20-year cohort.Br J Haematol2012
20868761Adult dual umbilical cord blood transplantation using myeloablative total body irradiation (1350 cGy) and fludarabine conditioning.Biol Blood Marrow Transplant2011
21865344Ontogeny stage-independent and high-level clonal expansion in vitro of mouse hematopoietic stem cells stimulated by an engineered NUP98-HOX fusion transcription factor.Blood2011
21730353Prolonged self-renewal activity unmasks telomerase control of telomere homeostasis and function of mouse hematopoietic stem cells.Blood2011
21042312Long-term follow-up of patients undergoing auto-SCT for advanced germ cell tumour: a multicentre cohort study.Bone Marrow Transplant2011
21133716Novel agents improve survival of transplant patients with multiple myeloma including those with high-risk disease defined by early relapse (&lt;12 months).Leuk Lymphoma2011
19597425Long-term outcome after allo-SCT: close follow-up on a large cohort treated with myeloablative regimens.Bone Marrow Transplant2010
20005967Response to tyrosine kinase inhibitor therapy in patients with chronic myelogenous leukemia relapsing in chronic and advanced phase following allogeneic hematopoietic stem cell transplantation.Biol Blood Marrow Transplant2010
18762338Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels.Leuk Res2009
19903289Platelet quality measured with dynamic light scattering correlates with transfusion outcome in hematologic malignancies.Transfusion2009
19377048Prospective isolation and molecular characterization of hematopoietic stem cells with durable self-renewal potential.Blood2009
19167680IPSS poor-risk karyotype as a predictor of outcome for patients with myelodysplastic syndrome following myeloablative stem cell transplantation.Biol Blood Marrow Transplant2009
19135941Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma.Biol Blood Marrow Transplant2009
  • 1 - 50 of 93

Recommended Authors

Sawa Ito
University of Pittsburgh
Career Start Year 2013
Number of shared co-authors 1
Friedrich St??lzel
University Hospital TU Dresden
Career Start Year 2008
Number of shared co-authors 2
Tara L Lin
University of Kansas Medical Center
Career Start Year 2004
Number of shared co-authors 8
Laura F Newell
Oregon Health and Science University
Career Start Year 2003
Number of shared co-authors 3
Eneida R Nemecek
Oregon Health Sciences University
Career Start Year 2002
Number of shared co-authors 7
Peter Kurre
Children's Hospital of Philadelphia
Career Start Year 1999
Number of shared co-authors 3
Emmanuel Raffoux
Universite Paris Diderot
Career Start Year 1998
Number of shared co-authors 0
Ravindra Majeti
Stanford University School of Medicine
Career Start Year 1998
Number of shared co-authors 5
Stephanie Halene
Smilow Cancer Center, Yale University School of Medicine
Career Start Year 1997
Number of shared co-authors 0
Bruno C Medeiros
AbbVie Inc.
Career Start Year 1996
Number of shared co-authors 9
Michael Heuser
Hannover Medical School
Career Start Year 1993
Number of shared co-authors 6
Ravi Bhatia
University of Alabama at Birmingham
Career Start Year 1992
Number of shared co-authors 6
Jose A Cancelas
Cincinnati Children's Hospital Medical Center
Career Start Year 1990
Number of shared co-authors 3
Peter Westervelt
Washington University School of Medicine
Career Start Year 1990
Number of shared co-authors 2
Jerald P Radich
Fred Hutchinson Cancer Center
Career Start Year 1989
Number of shared co-authors 8
Koen van Besien
University Hospitals of Cleveland
Career Start Year 1988
Number of shared co-authors 3
Robert H Collins
University of Texas Southwestern Medical Center
Career Start Year 1987
Number of shared co-authors 10
Richard J Jones
Sidney Kimmel Cancer Center, Johns Hopkins University
Career Start Year 1986
Number of shared co-authors 1
Alan S Wayne
Cancer and Blood Disease Institute, Children's Hospital Los Angeles
Career Start Year 1986
Number of shared co-authors 5
Richard M Stone
Dana Farber Cancer Institute
Career Start Year 1986
Number of shared co-authors 7
Denis-Claude Roy
Universite de Montreal
Career Start Year 1985
Number of shared co-authors 3
Herv?? Dombret
Institut de Recherche Saint-Louis, Universite de Paris
Career Start Year 1984
Number of shared co-authors 0
Richard T Maziarz
Oregon Health & Science University
Career Start Year 1983
Number of shared co-authors 5
Hagop Kantarjian
The University of Texas MD Anderson Cancer Center
Career Start Year 1982
Number of shared co-authors 9
Dietger Niederwieser
University of Leipzig
Career Start Year 1982
Number of shared co-authors 2
Martin S Tallman
Memorial Sloan-Kettering Cancer Center
Career Start Year 1982
Number of shared co-authors 6
Kenneth B Miller
Tufts Medical Center
Career Start Year 1981
Number of shared co-authors 0
John E Dick
Princess Margaret Cancer Centre, University Health Network
Career Start Year 1980
Number of shared co-authors 7
John F DiPersio
Washington University School of Medicine
Career Start Year 1978
Number of shared co-authors 3
Curt I Civin
Center for Stem Cell Biology & Regenerative Medicine and.
Career Start Year 1976
Number of shared co-authors 2

Collaborators

Daniel A Pollyea
University of Colorado Division of Hematology
Co-authored papers 25
Veronica Clavijo Jordan
Harvard Medical School
Co-authored papers 22
Brett M Stevens
University of Colorado School of Medicine
Co-authored papers 19
Shanshan Pei
Zhejiang University Medical Center
Co-authored papers 14
Maura Gasparetto
University of Colorado School of Medicine
Co-authored papers 14
Amanda Winters
University of Colorado School of Medicine
Co-authored papers 12
Diana Abbott
Center for Innovative Design and Analysis, University of Colorado, Aurora CO.
Co-authored papers 11
Mohammad Minhajuddin
University of Colorado School of Medicine
Co-authored papers 11
Angelo D'Alessandro
University of Colorado Anschutz Medical Campus
Co-authored papers 8
Maria Amaya
University of Colorado School of Medicine
Co-authored papers 7
Joanne Kurtzberg
Marcus Center for Cellular Cures, Duke University School of Medicine
Co-authored papers 6
Courtney L Jones
Princess Margaret Cancer Centre, University Health Network
Co-authored papers 6
Travis Nemkov
University of Colorado Anschutz Medical Campus
Co-authored papers 6
Biniam Adane
The Broad Institute of MIT and Harvard
Co-authored papers 6
David A Rizzieri
Duke University Medical Center
Co-authored papers 5
Haobin Ye
Institute of Metabolism & Integrative Biology, Fudan University
Co-authored papers 5
Anna Krug
University of Colorado School of Medicine
Co-authored papers 5
Rachel Culp-Hill
University of Colorado Anschutz Medical Campus
Co-authored papers 5
Ryan R Brinkman
University of British Columbia
Co-authored papers 4
Anagha Inguva
University of Colorado School of Medicine
Co-authored papers 4
James DeGregori
University of Colorado Anschutz Medical Campus
Co-authored papers 3
Barton F Haynes
Co-authored papers 3
Michael W Becker
James P. Wilmot Cancer Institute, University of Rochester Medical Center Rochester
Co-authored papers 3
Julie A Reisz
University of Colorado Anschutz Medical Campus
Co-authored papers 3
Josef Spidlen
British Columbia Cancer Research Center
Co-authored papers 2
Subhajyoti De
Co-authored papers 2
Christopher R Cogle
College of Medicine, University of Florida
Co-authored papers 2
Kirk C Hansen
University of Colorado Anschutz Medical Campus
Co-authored papers 2
James C S Wood
Comprehensive Cancer Center
Co-authored papers 1
Elaine S Jaffe
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Co-authored papers 1
Release 1.2